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Abstract Frontotemporal lobar degeneration (FTLD) is
the umbrella term encompassing a heterogeneous group of
pathological disorders. With recent discoveries, the FTLDs
have been show to classify nicely into three main groups
based on the major protein deposited in the brain: FTLD-tau,
FTLD-TDP and FTLD-FUS. These pathological groups, and
their specific pathologies, underlie a number of well-defined
clinical syndromes, including three frontotemporal dementia
(FTD) variants [behavioral variant frontotemporal dementia
(bvFTD), progressive non-fluent aphasia, and semantic
dementia (SD)], progressive supranuclear palsy syndrome
(PSPS) and corticobasal syndrome (CBS). Understanding
the neuropathological background of the phenotypic
variability in FTD, PSPS and CBS requires large clinico-
pathological studies. We review current knowledge on the
relationship between the FTLD pathologies and clinical
syndromes, and pool data from a number of large clinico-
pathological studies that collectively provide data on 544
cases. Strong relationships were identified as follows: FTD
with motor neuron disease and FTLD-TDP; SD and FTLD-
TDP; PSPS and FTLD-tau; and CBS and FTLD-tau. How-
ever, the relationship between some of these clinical
diagnoses and specific pathologies is not so clear cut. In
addition, the clinical diagnosis of bvFTD does not have a
strong relationship to any FTLD subtype or specific pathol-
ogy and therefore remains a diagnostic challenge. Some
evidence suggests improved clinicopathological association
of bvFTD by further refining clinical characteristics. Unlike
FTLD-tau and FTLD-TDP, FTLD-FUS has been less well
characterized, with only 69 cases reported. However, there
appears to be some associations between clinical phenotypes
and FTLD-FUS pathologies. Clinical diagnosis is therefore
promising in predicting molecular pathology.
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AD Alzheimer’s disease
3R Three repeat
4R Four repeat
FTLD-tau FTLD characterized by tau immunoreactive
inclusions
FTLD-TDP FTLD characterized by TDP-43
immunoreactive inclusions
FTLD-FUS FTLD characterized by FUS
immunoreactive inclusions
FTLD-other Unclassified FTLD (not characterized by
tau, TDP-43 or FUS immunoreactive
inclusions)
FTLD-MND FTLD with motor neuron degeneration
FTLD-U FTLD with ubiquitin-only immunoreactive
inclusions
PiD Pick’s disease
PSP Progressive supranuclear palsy
CBD Corticobasal degeneration
AGD Argyrophilic grains disease
MST Sporadic multisystem tauopathy with
globular inclusions
DNTC Diffuse neurofibrillary tangle dementia
with calcifications
NIFID Neuronal intermediate filament inclusion
disease
BIBD Basophilic inclusion body disease
aFTLD-U Atypical FTLD with ubiquitin-only
immunoreactive changes
FTLD-ni FTLD without inclusions
FTLD-UPS FTLD with immunohistochemistry against
proteins of the ubiquitin proteosomal
system
NCI Neuronal cytoplasmic inclusions
H&E Hematoxylin and eosin
NFT Neurofibrillary tangle
Clinical terms
FTD Frontotemporal dementia
bvFTD Behavioral variant of FTD
MND Motor neuron disease
FTD-MND Frontotemporal dementia with motor neuron
disease
SD Semantic dementia
PNFA Progressive non-fluent aphasia
AOS Apraxia of speech
PSPS Progressive supranuclear palsy syndrome
CBS Corticobasal syndrome
PLS Primary lateral sclerosis
VSGP Vertical supranuclear gaze palsy
Genetic terms
CHMP2B Charged multivesicular body protein 2B
MAPT Microtubule associated protein tau
GRN Progranulin
VCP Valosin containing protein
TARDBP Transactive response DNA binding protein
Introduction
The term frontotemporal dementia (FTD) is reserved for a
cluster of syndromes that manifest as a result of patho-
logical damage to the frontal and temporal lobes [14, 94]. It
encompasses three main clinical syndromes: behavioral
variant FTD (bvFTD); progressive non-fluent aphasia
(PNFA) and semantic dementia (SD) [94]. The prevalence
of FTD has been estimated to be approximately 15 per
100,000 [102] while the incidence ranges from 2.2 to 8.9
per 100,000 depending on the age of onset [70]. In addi-
tion, some patients present with features of FTD, as well as
motor neuron disease (MND). When these two phenomena
co-occur, the syndromic diagnosis rendered is FTD-MND
[23, 46]. Two other syndromes, progressive supranuclear
palsy syndrome (PSPS) [78] and corticobasal syndrome
(CBS) [8] are closely related to the FTDs. These six clin-
ical syndromes are linked to a number of molecular
pathologies that target the frontal and temporal lobes,
known as the frontotemporal lobar degenerations (FTLDs)
[48].
Unlike FTD which is a clinical term, FTLD is a
pathological term [87]. Like FTD, the term FTLD
encompasses a cluster of diseases, in this instance, a
cluster of molecular pathologies [48]. These molecular
pathologies are classified according to the major bio-
chemical abnormality identified at post-mortem, i.e. the
major protein deposited.
Understanding the relationship between FTLD, FTD,
PSPS and CBS has proven challenging. Over the last
decade, many researchers have investigated the neuro-
pathological background of the phenotypic variability of
FTD, PSPS and CBS. Together these studies have
identified variable associations between specific clinical
syndromes and molecular pathologies. This review will
address the relationship of the FTLD molecular pathol-
ogies to the associated clinical syndromes of FTD, PSP
and CBS by dissecting each clinical syndrome and
molecular pathology. In addition, we pool data from
several large clinicopathological studies assessing 544
cases (Table 1) in order to determine associations
between clinical syndromes and molecular pathologies.
Chi-square tests were performed to assess the strengths
of the associations between clinical syndromes and
molecular pathologies. These studies were all from dif-
ferent institutions and all studies were reviewed in detail
to remove any overlapping cases.
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The frontotemporal lobar degenerations
The frontotemporal lobar degenerations (FTLDs) are a
heterogeneous group of diseases that overlap in gross and
histological features. All are associated with varying
degrees of atrophy, neuronal loss and gliosis of the frontal
and temporal lobes. However, each disease differs from
one another by differences in protein deposition or bio-
chemical signature, and inclusion morphology and
distribution [15]. Three major proteins have been identified
as leading players in the mechanism of neurodegeneration
of the FTLDs. These three proteins are the microtubule-
associated protein, tau [43], the transactive response DNA
binding protein of 43 kD (TDP-43) [1, 98], and the tumor
associated protein fused in sarcoma (FUS) [75]. Therefore,
at the highest stratum, the majority of FTLDs can be sub-
classified into FTLD-tau, FTLD-TDP and FTLD-FUS [84],
based on the biochemical signature of the abnormally
deposited protein (Fig. 1). Further sub-classification within
each of these three groups is predominantly based on
inclusion morphology and lesion distribution [15, 84, 85],
although other characteristics may also be utilized, such as,
tau isoform dominance, phosphorylation and ubiquitination
status, and cleavage sites. Using this classification scheme
Table 1 Studies used to gather data for clinicopathological associations of FTLD-tau and FTLD-TDP
Study Hodges et al.
[38]
Kertesz et al.
[67]
MacKenzie
et al. [80]/
Davidson
et al. [25]
Josephs et al. [56] Forman et al.
[31]
Snowden
et al. [111]
Grossman
et al. [35]
Josephs et al.
[57]
Institution Sydney,
Australia
and
Cambridge,
UK
London,
Ontario,
Canada
Manchester,
UK
Rochester, MN,
USA
Philadelphia, PA,
USA
Manchester,
UK
Philadelphia,
PA, USA
Jacksonville,
FL, USA
Study
criteria
Path proven
FTLD or
CBD from
dementia
clinics.
Excluded
PSP
Clinical
diagnosis
of FTD,
CBS or
PSP that
went to
autopsy
Path
diagnosis
of FTLD-
U or
FTLD-
MND.
Path diagnosis of
FTLD, CBD or
PSP from
movement
disorders and
dementia clinics
Clinical
diagnosis of
dementia as
well as FTLD,
CBD or PSP
path diagnosis
Path
diagnosis
of FTLD or
CBD from
a cerebral
function
unit
Path
diagnosis
of FTLD-
U or
FTLD-
MND
Path
diagnosis
of FTLD-
U or
FTLD-
MND
No. of cases reported
Total 61 60 37 127 90 65 23 39
Tau 31 21 0 87 53 25 0 0
TDP 30 24 37 39 37 40 23 39
FUS 0 0 0 0 0 0 0 0
Other 0 15 0 1 0 0 0 0
No. of FTLD pathological cases reported that had syndromic diagnoses of bvFTD, PNFA, SD, FTD-MND, CBS or PSPS
Total 61 33a 37 119 0b 62 18d 39
Tau 31 13 0 80 0 22c 0 0
TDP 30 20 37 39 0 40 18 39
FUS 0 0 0 0 0 0 0 0
Fig. 2a X X – X X X – –
Fig. 2b – – X – – – X X
Fig. 8 X X – X – X – –
Fig. 9a X X – X – X – –
Fig. 9b – – X – – – X X
a 22 cases were diagnosed as PPA, and could not be classified as PNFA or SD, and 5 cases were not included in the review since they did not
have an FTLD, CBD or PSP pathological diagnosis
b Specific clinical diagnoses (bvFTD, PNFA, SD, FTD-MND, CBS or PSPS) were not provided separately for the FTLD-tau and FTLD-TDP
cases
c Three patients were diagnosed with apraxia (PAX), but not CBS
d Three cases had a clinical diagnosis of AD and two had a clinical diagnosis of dementia with Lewy bodies
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almost 100% of the FTLDs can be sub-classified, with only
a handful of extremely rare cases remaining unclassified
(FTLD-other).
FTLD-tau
The FTLD-tau group consists of diseases in which the
major abnormal protein, identified by immunohistochem-
istry, is the microtubule-associated protein, tau. This group
consists of the following diseases: Pick’s disease (PiD) [28,
29], progressive supranuclear palsy (PSP) [37], cortico-
basal degeneration (CBD) [30], argyrophilic grains disease
(AGD) [11, 12], sporadic multisystem tauopathy with
globular inclusions (MST) [7, 53, 73], and diffuse neuro-
fibrillary tangle dementia with calcifications (DNTC) [71,
72] (Fig. 1). Combining data from five large clinicopath-
ological studies [31, 38, 56, 67, 111] of 544 pathologically
confirmed FTLD patients, it appears that some FTLD-tau
pathologies are much more common than others. The most
common pathology was CBD accounting for 35% of cases,
followed by PSP with 31%, PiD with 30% and AGD
accounting for the remaining 4% of all FTLD-tau (Fig. 2a).
No cases of MST or DNTC were reported in any of these
large clinicopathological studies. It should be noted that
PSP in general is a more common pathology than CBD
suggesting a recruitment bias likely driven by the fact that
these autopsy cases were mainly from dementia clinics.
These studies only recruited patients with FTD-like diag-
noses, some even excluded PSPS, and therefore patients
with relatively pure motor syndromes without prominent
behavioral changes would not have been included in these
series; hence it is no surprise that PSP was less common
than CBD since cognitive impairment is more likely a
feature of CBD than PSP (manuscript in press).
The characteristic histological features of the FTLD-tau
molecular pathologies are shown in Figs. 3, 4. Unlike the
other diseases in this category, PiD is a 3 repeat (3R)
tauopathy [13], i.e. deposited tau is characterized by 3
binding domains in the carboxyl terminus of the protein, as
opposed to 4 binding domains (4R) in PSP [20], CBD
[115], AGD [119] and MST [7]. A mixture of 3R and 4R
binding domains is observed in intracellular neurofibrillary
tangles in DNTC [45], although extracellular tangles (ghost
tangles) are predominantly 3R tau (Fig. 4). Additional
features differentiating PiD from the other pathologies are
the rounded appearance of the inclusions, the fact that
inclusions are strongly argyrophilic but do not stain with
Gallyas [120, 121], and are localized to the cytoplasm of
the neuron, and the absence of features typical for the other
diseases [28, 29]. Unlike PiD, neuronal inclusions in PSP
are much larger and globose in morphology. In addition,
PSP is characterized by the presence of astrocytic lesions,
Fig. 1 Diagram illustrating the
current classification scheme for
the FTLDs. FTLD-tau
pathologies are shown in green,
FTLD-TDP in red, FTLD-FUS
in yellow and FTLD-other in
blue. The genes associated with
each pathological group are also
shown. FTLD-TDP typing (1–3)
is based on the classification by
Mackenzie et al.; type 4 is based
on the classification of Cairns
et al. 9p Linkage identified on
chromosome 9P
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better known as tufted astrocytes. Corticobasal degenera-
tion, like PSP, can show large neuronal inclusions, but they
tend to be more rounded (so called cortico-basal bodies)
[33]. In addition, CBD is characterized by the presence of a
different type of astrocytic lesion, known as the astrocytic
plaque [30]. In CBD, unlike in PSP, there is also wide-
spread white matter pathology where numerous thread-like
lesions are easily identified. There is also a biochemical
difference between PSP and CBD, with PSP showing a
33-kD tau band on immunoblots of sarkosyl-insoluble
brain extracts while CBD shows a 37-kD band [2]. Given
these differences, many researchers have continued to
support splitting PSP and CBD [27]. The other two FTLD-
tau entities are characterized by: the presence of globular
oligodengroglial inclusions in MST [7, 53, 73]; and a
prominence of widespread intracellular neurofibrillary
tangles and ghost tangles with intraparenchymal calcifica-
tion in DNTC [71].
There are very good clinicopathological associations
between FTLD-tau as a group, FTD, PSPS and CBS which
are discussed below. However, it is still difficult to dif-
ferentiate the individual pathologies, such as PSP from
CBD, based solely on clinical presentation. The other
entities in this group, MST, AGD and DNTC are rare when
compared to PiD, PSP and CBD with only a handful of
case reports or small case series of each of these patholo-
gies being associated with FTD, PSPS or CBS [7, 26, 44,
45, 53, 71, 73, 93]. Therefore, no strong clinicopathologi-
cal associations exist for MST, AGD and DNTC.
FTLD-TDP
Similar to FTLD-tau, classification of the subtypes of
FTLD-TDP is based on the morphological appearance of
the inclusions and the distribution of the lesions. Four
subtypes of FTLD-TDP are currently recognized (Fig. 1)
[15, 80, 105], although overlap across subtypes have been
reported [3]. FTLD-TDP types 1–3 have been described in
two different classification schemes by MacKenzie et al.
and Sampathu et al. [80, 105], although each classification
scheme maps well onto the other. Therefore, FTLD-TDP
type 1 in Mackenzie’s scheme maps to FTLD-TDP type 3
in Sampathu’s scheme; Mackenzie’s type 2 maps to
Sampathu’s type 1 and Mackenzie’s type 3 maps to
Sampathu’s type 2. In this review we use the Mackenzie’s
classification scheme since that scheme was initially shown
to have good association with clinical phenotype. Based on
data from four clinicopathological studies [35, 57, 80, 111],
the most common subtype was FTLD-TDP type 1
accounting for 41% of cases followed by FTLD-TDP type
3 with 34% and then FTLD-TDP-type 2 with 25%
(Fig. 2b). There were no cases of FTLD-TDP type 4 in any
of these large clinicopathological studies.
In Mackenzie’s scheme, FTLD-TDP type 1 is charac-
terized by a combination of neuronal cytoplasmic
inclusions (NCI) and short, comma shaped, dystrophic
neurites in frontotemporal cortex, as well as the common
occurrence of neuronal intranuclear inclusions; FTLD-TDP
type 2 by a predominance of long thicker dystrophic neu-
rites and minimal to absent NCI in frontotemporal cortex,
and FTLD-TDP type 3 by a predominance of NCI in
frontotemporal cortex or the dentate granule cell layer of
the hippocampus and absent to minimal dystrophic neurites
in cortex (Fig. 5). FTLD-TDP type 4 is characterized by a
predominance of intranuclear inclusions, dystrophic neu-
rites and absent to little NCI [95], and is associated with
mutations in the valosin containing protein gene [128].
There is good association between FTLD-TDP types and
clinical syndromes as discussed below.
FTLD-FUS
This newest FTLD category consists of three relatively rare
diseases: neuronal intermediate filament inclusion disease
(NIFID) [16, 52], basophilic inclusion body disease
(BIBD) [74] and atypical FTLD with ubiquitin-only
Fig. 2 Pie charts showing the proportion of specific pathologies
observed in FTLD-tau (a) and FTLD-TDP (b), based on pooled data
from eight large clinicopathological studies. The number and
percentage associated with each pathology is also shown. FTLD-
TDP typing is based on the classification by Mackenzie et al.
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immunoreactive changes (aFTLD-U) [54, 82, 103] (Fig. 1).
These three entities share the fact that they all show
striking FUS immunoreactivity [92, 96, 97], but there are
differences between each of them that allow each to be
considered a separate pathological entity (Fig. 6). The first,
NIFID, originally known as neurofilament inclusion body
disease [52], is characterized by the presence of variable
shaped inclusions that appear more eosinophilic on hema-
toxylin and eosin (H&E), variable immunoreactivity to
ubiquitin, but strikingly immunoreactivity to intermediate
filaments, including neurofilament and alpha-internexin
[18, 58, 122]. Similar to NIFID, in BIBD, the inclusions are
visible on H&E, although in BIBD the inclusions appear
basophilic. Unlike in NIFID, antibodies to epitopes of
neuronal intermediate filaments do not immunostain the
neuronal inclusions, however, like NIFID, ubiquitin stain-
ing is variable in BIBD. The third FTLD-FUS entity,
aFTLD-U, differs from both NIFID and BIBD as inclusions
are not observed on H&E. In addition, aFTLD-U can be
further differentiated from NIFID since the inclusions are
not immunoreactive to intermediate filaments, and can be
further differentiated from BIBD since vermiform intra-
nuclear inclusions present in aFTLD-U are absent or rare in
BIBD [83]. Motor neuron degeneration is found in around
50% of NIFID and BIBD cases but has not been reported in
aFTLD-U. One feature that appears to be characteristic of
the FTLD-FUS group is striking early caudate atrophy [63,
106]; by the time of autopsy, the caudate nucleus usually
has a concave appearance.
FTLD-other
The FTLD-other category is reserved for diseases in which
the major protein associated with the disease entity remains
unknown. Currently, there are two rare pathological enti-
ties in this category [123]. The first, FTLD without
inclusions (FTLD-ni), is diagnosed when there is histo-
logical evidence of frontotemporal neuronal loss and
gliosis but all routine and immunohistochemical stains fail
to reveal the presence of any inclusions. The term FTLD-
ni is the preferred terminology, replacing the older terminol-
ogy of dementia lacking distinctive histology. The second,
Fig. 3 Histological features of the more common 4R FTLD-tau
molecular pathologies. PSP features, including globose NFT with
H&E (a) and tau (b), and a tufted astrocyte (c) with tau immuno-
histochemistry. CBD features, including ballooned neurons with H&E
(d), and pretangles in basal nucleus (e) and astrocytic plaques in the
cortex (f) both with tau immunohistochemistry. Features of a
MAPT mutation (P301L) with tau deposition, including ballooned
neurons with H&E (g) and threads, ballooned neurons and
pretangles in cortex (h), and pretangles in dentate fascia (i) with
tau immunohistochemistry
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FTLD with immunohistochemistry against proteins of the
ubiquitin proteosomal system (FTLD-UPS), is diagnosed
when there are ubiquitin or p62 immunoreactive inclusions,
that are negative to tau, alpha-synuclein, alpha-internexin,
TDP-43 and FUS. The majority of FTLD-UPS cases are
associated with mutations in the charged multivesicular
body protein 2B (CHMP2B) gene [40], although a few
sporadic cases exist [123]. The FTLD-other category may
also be used for extremely rare FTLD cases that do not
conform to the pathological criteria discussed above.
The frontotemporal dementias
Three classic syndromes are subsumed under the rubric of
frontotemporal dementia (FTD): bvFTD, PNFA and SD
[94]. The behavioral variant of FTD is characterized by
changes in behavior and personality, resulting in disruption
of social interactions. Executive dysfunction is common.
Symptoms suggestive of the diagnosis of bvFTD include
apathy, disinhibition, poor planning, poor organization,
hyperactive behaviors such as wandering and pacing, as
well as changes in eating, sleeping and sexual behaviors.
The age of onset of patients with bvFTD is typically less
than 65 years with an average age of onset around 58 [47].
The syndrome of bvFTD can be associated with many
different FTLD pathologies. However, given recent
molecular pathological discoveries, some investigators
have argued that there may be subtypes of bvFTD that
more tightly link to specific molecular pathologies (Fig. 7).
Recent clinicopathological studies have identified, for
example, a clinical syndrome of behavioral and personality
change dominated by hypersexual and hyperphagic
behaviors, prominent stereotypy and obsessionality that
tightly links to the molecular pathology of aFTLD-U [113,
123]. This finding links two previous reports of (1) striking
striatal atrophy in patients with bvFTD and stereotypy [61],
and (2) striking striatal atrophy in aFTLD-U [63]. An
additional feature common to these patients is a very young
age at onset, as patients tend to present with a mean age of
onset of around 40 years. Another less well-established
association is that of bvFTD with psychosis and FTLD-
Fig. 4 Histological features of the 3R, 3R ? 4R and remaining 4R
FTLD-tau molecular pathologies. Features of Pick disease, including
globose Pick bodies in dentate fascia with H&E (a) and with 3R tau
(b), but negative for 4R tau (c). Features of DNTC, including
extracellular NFT with H&E (d) and with 3R tau (e), but mostly
negative for 4R tau (note some neurites and glial 4R tau immuno-
reactivity) (f). Features of AGD, including argyrophilic grains with
Bielschowsky (g) and sparse pretangles but negative grains with 3R
tau (h), and many grains with 4R tau (i)
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TDP type 3 with MND [76]. Unlike bvFTD associated with
aFTLD-U, bvFTD associated with FTLD-TDP type 3 tends
to have a more typical age of onset; patients are also not
hypersexual, stereotypic or hyperphagic. This latter bvFTD
with psychosis sub-syndrome is reminiscent of the syn-
drome of dementia with Lewy bodies [22]. One could
argue that these ‘sub-syndromes’ are all bvFTD, although
there appears to be benefit in separating these sub-syn-
dromes in order to better predict the underlying molecular
pathology (Fig. 7).
The syndrome of PNFA is characterized by ‘non-fluent’
speech output with agrammatic and telegraphic speech
[94]. Frequently accompanying the aphasia is a motor
speech disorder known as apraxia of speech (AOS) [51,
99]. Many researchers do not separate AOS from PNFA
and hence the term PNFA typically implies the presence of
aphasia and AOS [34]. Detailed studies of PNFA, however,
have demonstrated that the presence of AOS is tightly
associated with FTLD-tau, especially PSP and CBD [26,
51]. Neuroanatomic studies have also demonstrated that the
presence of AOS correlates with atrophy of the premotor
and supplemental motor cortices [51], regions that are
prominently and focally affected in PSP and CBD. It is
therefore not surprising that the most common pathologies
underling AOS, and hence PNFA, are PSP and CBD, as
discussed below. Predicting PSP over CBD, and vice versa,
is difficult in PNFA, although there is some evidence to
suggest that pure or dominant AOS is more suggestive of
PSP, while AOS plus prominent aphasia is more suggestive
of CBD [50]. This hypothesis would be supported by the
fact that CBD pathology is associated with slightly less
focal atrophy than PSP [59], and tends to also involve the
inferior posterior lateral frontal lobe or Broca’s area [129].
It remains to be determined whether aphasia without AOS
is linked to a specific molecular pathology but evidence
exists to suggest that it is linked to FTLD-TDP [26], par-
ticularly FTLD-TDP type 1 pathology [111], as discussed
below.
The term SD is reserved for a clinical syndrome char-
acterized by fluent speech with prominent anomia, loss of
word and object meaning, and poor single word compre-
hension [110, 127]. The clinical syndrome of SD has been
found to highly associate with FTLD-TDP type 2 pathol-
ogy [39, 57, 80, 111]. Patients with SD commonly present
with aphasia that is associated with left anterior medial
temporal lobe atrophy [21, 91]. The right temporal lobe is
typically also affected in SD, and in some instances is even
more atrophic than the left [118]. In such cases of right
Fig. 5 Histological features of FTLD-TDP types based on the
classification of Mackenzie et al. a Features of FTLD-TDP type 1
(Sampathu, type 3) including short, thin neurites and pleomorphic
neuronal cytoplasmic inclusions (NCI) with neuronal intranuclear
inclusions (upper inset). b shows features of FTLD-TDP type 2
(Sampathu, type 1) including long, thick neurites in cortex (upper
inset) as well as a Pick-body-like NCI in dentate fascia (lower inset).
c Features of FTLD-TDP type 3 (Sampathu, type 2) including NCI
and granular cytoplasmic staining (pre-inclusions—upper inset)
with irregular granular NCI in dentate fascia (lower inset).
c, d Features of FTLD-TDP type 4 including NCI, neurites and many
neuronal intranuclear inclusions (lower insets). All with TDP-43
immunohistochemistry
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greater than left temporal lobe atrophy, the clinical pre-
sentation of SD is dominated, not by aphasia, but by
prosopagnosia and behavioral dyscontrol [64, 107, 118].
Not surprisingly, therefore, behavioral changes have been
shown to be prominent in SD [112]. Unlike the anomic
presentation of SD that has been strongly associated with
FTLD-TDP type 2 pathology, the behavioral/proso-
pagnostic presentation of SD is more easily confused with
bvFTD. Detailed studies on SD, however, have shown that
the behavioral/prosopagnostic presentation of SD also links
to FTLD-TDP type 2 pathology. One study suggested that
the presence or absence of prosopagnosia is helpful in
differentiating SD with greater right temporal lobe atrophy
and behavioral features from bvFTD with prominent right
temporal lobe atrophy [62]. This is important since it
appears that bvFTD with prominent right temporal lobe
atrophy is associated with FTLD-tau pathology [62].
Some patients present with symptoms suggestive of a
diagnosis of FTD, however, clinical and electrophysio-
logical examination confirms coexisting MND (FTD-
MND) [23, 79]. In FTD-MND, the FTD syndrome is typ-
ically characterized by behavioral change, although cases
with prominent aphasia have been described [19]. The
MND domain can be characterized by bulbar problems
such as swallowing or speech difficulties [42, 76], although
limb weakness associated with fasciculations in the weak
limb is also common. Signs of upper motor neuron disease
or pyramidal tract signs, such as spasticity, hyper-reflexia,
Babinski and clonus, are less common, but have been
described [55]. A clinical diagnosis of FTD-MND has
almost perfect association with molecular pathology as
revealed below.
Progressive supranuclear palsy and corticobasal
syndromes
The terms PSPS and CBS are reserved for clinical diag-
nosis, while the terms PSP and CBD are now reserved for
pathological diagnosis. Progressive supranuclear palsy
Fig. 6 Histological features of FTLD-FUS molecular pathologies.
Features of aFTLD-U, including striking striatal atrophy (a), neuronal
cytoplasmic inclusions (NCI) (b) and vermiform neuronal intranu-
clear inclusions (c) with FUS immunohistochemistry. Features of
NIFID, including internexin positive NCI (note weak cytoplasmic
staining in pyramidal neurons) (d) and FUS positive NCI in cortex
with FUS immunohistochemistry (e). Features of BIBD with juvenile
motor neuron disease, including large basophilic cytoplasmic inclu-
sions (f) that are positive with FUS immunohistochemistry (g)
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syndrome is characterized by a symmetric akinetic syn-
drome with prominent axial rigidity, vertical supranuclear
gaze palsy (VSGP) and early falls [131]. Apathy is com-
mon in PSPS, while other behavioral and personality
changes are less common [4, 10, 60]. A diagnosis of classic
PSPS, i.e. without prominent behavioral dyscontrol, is
highly predictive of PSP pathology [56]. Recent evidence
suggests, however, that patients with VSGP, as in PSPS,
but prominent behavioral dyscontrol and dementia as in
bvFTD, may actually more likely be CBD, instead of PSP
(manuscript in press) (Fig. 7). Corticobasal syndrome is
characterized by asymmetric cortical and extrapyramidal
signs occurring together [8]. Cortical signs include limb
apraxia, action-induced myoclonus and alien limb phe-
nomenon, while limb rigidity and dystonia are relatively
common extrapyramidal features. Unfortunately, CBS
shows poor association to any single molecular pathology
[9], although CBD and PSP, both FTLD-tau, account for
the majority of cases of CBS.
Clinicopathological associations
Four large studies representing work from six different
centers in the United States, Canada, United Kingdom and
Australia have been published on clinicopathological
associations between FTLD, and specific FTD, PSPS and
CBS clinical diagnoses [38, 56, 67, 111]. When data from
all four studies were pooled, variable clinicopathological
associations were observed. The observed proportions of
FTLD-tau to FTLD-TDP differed significantly across the
different clinical syndromes (p \ 0.0001) (Fig. 8). In
addition, the observed proportions of FTLD-tau to FTLD-
TDP differed from that expected by chance in all clinical
groups (p \ 0.05), except for bvFTD (p = 0.22). Almost
all cases of PSPS and CBS had FTLD-tau pathology, while
100% of FTD-MND cases had FTLD-TDP pathology.
Semantic dementia was associated with FTLD-TDP, with
83% of cases showing FTLD-TDP pathology, and PNFA
was associated predominantly with FTLD-tau (70%). The
bvFTD syndrome showed almost equal proportions of
FTLD-tau and FTLD-TDP.
Associations between clinical syndromes and specific
FTLD-tau pathologies are shown in Fig. 9a. The observed
proportions of FTLD-tau pathologies (PiD, CBD, PSP,
AGD) differed significantly across the different clinical
syndromes (p \ 0.0001). In addition, the observed pro-
portions of FTLD-tau pathologies differed from that
expected by chance in all clinical groups (p \ 0.05), except
for PNFA (p = 0.10). Of the patients diagnosed with SD
and having FTLD-tau pathology (n = 3), all showed PiD,
suggesting that PSP and CBD are extremely unlikely to be
associated with the SD syndrome. Another excellent
association was noted between PSPS and PSP pathology,
where over 90% of patients with PSPS had PSP, and the
remainder had CBD. Weaker associations were found
between the clinical diagnosis of bvFTD and pathology,
although the data showed that if bvFTD was associated
with FTLD-tau there was almost a 70% chance that the
pathology would be PiD. The diagnosis of PNFA was not
associated with any specific FTLD-tau pathology, and was
split almost equally between PiD, CBD and PSP. The most
common tau pathology associated with CBS was CBD,
followed by PSP and PiD.
For the FTLD-TDP group, when we pooled data we also
found variable clinicopathological associations [25, 35, 57,
Fig. 7 Diagram showing clinical features that help to predict the
underlying FTLD-tau, FTLD-TDP or FTLD-FUS molecular pathol-
ogy in patients presenting with bvFTD. VSGP vertical supranuclear
gaze palsy. FTLD-TDP types based on the classification of Macken-
zie et al.
Fig. 8 Bar chart showing the proportion of patients with FTLD-tau
or FTLD-TDP within each clinical diagnosis based on pooled data
from large clinicopathological studies. Actual number of subjects
with each clinical diagnosis is also shown
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80] (Fig. 9b). The observed proportions of FTLD-TDP
types differed significantly across the different clinical
syndromes (p \ 0.0001) and differed from that expected
by chance in all clinical groups (p \ 0.05). The strongest
associations were identified between FTD-MND and
FTLD-TDP type 3 pathology, between SD and FTLD-TDP
type 2 pathology, and between PNFA and FTLD-TDP type
1 pathology. These clinicopathological associations sup-
port the sub-typing of FTLD-TDP. Once again, bvFTD was
not as strongly associated with any one type, although the
most common was FTLD-TDP type 1. As mentioned ear-
lier, one has to wonder whether the syndrome of bvFTD is
too loose and hence needs to be revised. One has to also
wonder whether bvFTD associated with FTLD-TDP type 2
represents misdiagnosed cases of SD.
There are no large clinicopathological studies that take
into account FTLD-tau, FTLD-TDP and FTLD-FUS.
Therefore, less is known about associations between
FTLD-FUS, FTD, PSPS and CBS. With that said, there are
many small case series and a few large ones that allow us
to pool data on 69 FTLD-FUS cases and get a glimpse of
possible associations between clinical syndromes and
FTLD-FUS [16, 54, 58, 90, 92, 96, 97, 123] (Fig. 10). It
appears that NIFID is associated with three syndromes; the
most common of which is bvFTD (Fig. 10a). It can also be
associated with FTD-MND. A third syndrome associated
with NIFID is a CBS/primary lateral sclerosis (PLS) hybrid
which not only shows features of CBS but also prominent
upper motor neuron signs such as spasticity, Babinski and
clonus. On the flip side, one could say that this CBS/PLS
syndrome is characterized by asymmetric upper motor
neuron disease plus parkinsonism. Many syndromes can
underlie the pathology of BIBD including bvFTD, FTD-
MND, PSPS, CBS/PLS and others, such as, pure MND
(Fig. 10b) or juvenile amyotrophic lateral sclerosis. An
excellent association was, however, identified between
aFTLD-U and bvFTD (Fig. 10c), as discussed earlier.
There are no clinicopathological studies on FTLD-UPS
or FTLD-ni. Furthermore, less than a handful of such cases
exists [123] with the exception of the CHMP2B subtype of
FTLD-UPS which is discussed below.
Clinicopathological associations of genetic variants
of FTLD
Although the majority of FTLD cases are sporadic, a small
familial subset is associated with gene mutations. In many
instances, these gene mutations result in a syndrome pre-
senting similar to one of the syndromes described above. Six
genes are currently associated with FTLD. Mutations in the
microtubule-associated tau gene, MAPT [43], are typically
associated with neuronal and glial tau deposition (Fig. 3),
and although there is no consistent pattern to the tau depo-
sition [125] it can sometimes resemble other sporadic
tauopathies such as PiD, PSP and CBD [32]. Most com-
monly, patients with MAPT mutations present with a bvFTD-
like phenotype [100] in which extrapyramidal features may
also be present. Not surprisingly, however, given the prom-
inent anterior medial temporal lobe atrophy identified in
patients with a MAPT mutation [104, 130], an SD-like pre-
sentation associated with features of bvFTD (or bvFTD with
semantic impairment), in particular disinhibition, has also
been associated with MAPT mutations [62, 100, 111]
(Fig. 7). Another gene associated with familial FTLD is
progranulin (GRN) [5, 24]. Unlike MAPT that is associated
with tau, GRN mutations are associated with TDP-43
deposition; specifically FTLD-TDP type 1 pathology with
neuronal intranuclear inclusions [17, 49, 81]. It is now well
recognized that familial GRN is strongly associated with a
CBS-like presentation [66, 86, 116], as well as a PNFA-like
presentation [88, 111, 114] and a bvFTD-like presentation
[66], especially with apathy [101] (Fig. 7). Mutations in
Fig. 9 Bar charts showing the proportion of patients with specific
FTLD-tau (a) or FTLD-TDP (b) pathologies within each clinical
diagnosis, based on pooled data from large clinicopathological
studies. Actual number of subjects with each clinical diagnosis is
also shown. FTLD-TDP types based on the classification of
Mackenzie et al.
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other genes associated with FTLD pathology are extremely
rare and include mutations in the VCP gene [128], the
CHMP2B gene [109], the TDP-43 (TARDBP) gene [6] and
the FUS gene [132]. While mutations in the VCP gene are
associated with a syndrome combining FTD, Paget’s disease
of the bone and myopathy [128], mutations in CHMP2B are
typically associated with a bvFTD-like syndrome [36] and
has only been identified in two families to date [36, 124].
Mutations in the TARDBP and FUS genes are predominantly
associated with familial MND [65, 75, 117, 126], but rarely
with an FTD-like syndrome.
These genetic clinicopathological associations differ
somewhat from the clinicopathological associations iden-
tified in sporadic FTD and related disorders. For example,
clinical diagnoses of PNFA and CBS are more likely to be
associated with FTLD-tau in sporadic cases while in
familial cases they are more likely to be associated with
FTLD-TDP, particularly type 1, pathology. However, a
diagnosis of sporadic or familial bvFTD could be associ-
ated with either FTLD-tau or FTLD-TDP. Semantic
dementia and PSP are almost always sporadic.
Overlap with Alzheimer’s disease
Distinguishing FTLD from Alzheimer’s disease (AD) is
also of paramount importance. AD, like DNTC, is char-
acterized by 3R ? 4R tau deposition. Alzheimer’s disease
is usually associated with loss of episodic memory. How-
ever, there have been reports of AD being associated with
some variants of FTD, commonly PNFA, and CBS which
would not be captured in clinicopathological studies of
FTLD pathology [41, 67, 68, 77, 108]. Recent work has
revealed that AD is more likely present when the aphasia
syndrome is dominated by phonological errors, i.e. log-
openic progressive aphasia [89], a syndrome that can be
mistaken for PNFA. A diagnosis of frontal variant AD is
given when the ante-mortem clinical diagnosis is bvFTD
and the pathological diagnosis is AD. Such cases occur but
are rare, with AD pathology being reported in only 5–6%
of bvFTD cases [67, 69].
Summary
In this review, we have discussed the neuropathological
background of phenotypic variability of FTD. Some clinical
syndromes have good–excellent associations with the
FTLD pathological group, and even with specific molecular
pathologies. These syndromes allow for better prediction of
pathology than those syndromes with average-poor clini-
copathological associations. One such syndrome with
excellent prediction of underlying pathology is FTD-MND.
Other syndromes, however, show little association with a
single FTLD pathological group and even less association
with any single FTLD pathology. This latter finding, implores
us, as researchers, to continue to dissect the complex labyrinth
of FTLD.
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